Expertise
Viral vector development for gene delivery/gene therapy
Our Measles-derived Virosomes can be used as a Adeno/AAV viral vectors
CEO
SAGITTA BIOTECH
Liège, Liège, Belgium
Sagitta Biotech is a company developing vaccines from an innovative plaftorm. We are able to develop vaccines able to answer most unmet medical needs.
Phd in Immunology and MBA from Solvay.
Managing Biotech companies since 2003.
My organisation
Sagitta Biotech is developing innovative therapies against infectious diseases and cancer based on its viral vector/mRNA platform.
Sagitta's innovative platform is based on a reverse-engineering of the Measles virus, able to express up to 6 different antigen on its surface (including affinity proteins to infect cells carrying specific markers) and to deliver a self-replicating RNA in the cells.
The technology is being used to develop multivalent vaccines, oncology products or gene therapy vectors. We are looking for partners to evaluate our technology as a way to modify cells in vitro or in vivo (CAR T cell generation in vivo).
Skills
Interests
Expertise
Viral vector development for gene delivery/gene therapy
Our Measles-derived Virosomes can be used as a Adeno/AAV viral vectors